A landscape of therapeutic cooperativity in KRAS mutant cancers reveals principles for controlling tumor evolution

Article, Other literature type English OPEN
Anderson, Grace R.; Winter, Peter S.; Lin, Kevin H.; Nussbaum, Daniel P.; Cakir, Merve; Stein, Elizabeth M.; Soderquist, Ryan S.; Crawford, Lorin; Leeds, Jim C.; Newcomb, Rachel; Stepp, Priya; Yip, Catherine; Wardell, Suzanne E.; Tingley, Jennifer P.; Ali, Moiez; Xu, Mengmeng; Ryan, Meagan; McCall, Shannon J.; McRee, Autumn J.; Counter, Christopher M.; Der, Channing J.; Wood, Kris C.; (2017)
  • Publisher: Elsevier
  • Journal: Cell Reports (issn: 2211-1247)
  • Related identifiers: pmc: PMC5567854, doi: 10.1016/j.celrep.2017.07.006
  • Subject: pooled screening | SRC | synthetic lethality | BIM | PIK3CA | apoptosis | KRAS | Article | QH301-705.5 | drug resistance | CRISPR/Cas9 | Biology (General)
    mesheuropmc: neoplasms

Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize therapeutic responses are unclear. Using CRISPR/Cas9, we systematically mapped the ... View more
Share - Bookmark